质子抑制剂在移植患者中的使用:基于人口的研究
James Kiberd1, Robert R Quinn1,2, Pietro Ravani1,2
1Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Canadian journal of kidney health and disease
|February 15, 2024
概括
许多移植接受者继续长期使用质子抑制剂 (PPI),通常没有明确的迹象. 科专家应领导减缓处方的努力,以减少这些患者的多药性治疗.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 药理学 药理学是指药理学的学科.
- 胃肠病学 胃肠病学
背景情况:
- 接受移植的接受者经常接受质子抑制剂 (PPI).
- 长期使用PPI引发了对多种药物的担忧,并要求仔细考虑减产.
研究的目的:
- 在移植后的第一年以后,对移植接受者的PPI利用模式进行描述.
- 提供数据支持在这个人群中为PPI减 prescribing 举措.
主要方法:
- 基于人口的回顾性队列研究,利用加拿大阿尔伯塔省的链接医疗保健数据库.
- 包括成年仅接受脏移植的接受者以及随访数据.
- 分析PPI处方数据,包括频率,持续时间和确定的适应症.
主要成果:
- 在1823名受试者中,48%的人在基线时使用PPI;91%的随访时间涉及PPI使用.
- 科医生是PPI的主要处方者.
- 仅在54%的接受者中发现了PPI使用的明确迹象,而抗血小板治疗是最常见的原因.
结论:
- 很大一部分接受脏移植的人在移植后很长时间仍在使用PPI,通常没有文档说明.
- 科医生在PPI处方中发挥着关键作用,应该成为处方策略的核心.
- 减少不必要的PPI使用可以帮助减轻脏移植接受者的多药风险.
相关概念视频
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
431
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
431
Renal Failure: Dose Adjustments
89
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
89
Renal Drug Excretion: Tubular Secretion
183
Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...
183


